ABSTRACT: BACKGROUND: For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of rFVIIa, treatment failures were only rarely reported.
--
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 1/21/2006 06:54:49 PM
